LPPEPTIDE | KPV10 10mg | 10mg x 10 vials | 10 vials / box

What is KPV?

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.

Research context

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.

Commonly matched with

Plan based on an 8–16 week daily protocol with gradual titration. Peptide Vials (KPV, 10 mg each): 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 6 vials Insulin Syringes (U‑100): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution. 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles Alcohol Swabs: One for the vial stopper + one for the injection site each day. Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Reference literature focus

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.

Important Notes

Practical considerations for consistency and safety. Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use. Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy[8]. Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow. Document daily dose, injection site, and any observations to maintain consistency and track tolerability. If injection‑site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant protocol review.

LPPeptide handling reference

Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated[4][5]. Target: 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects. Frequency: Once per day (subcutaneous). Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring. Timing: Any consistent time; rotate injection sites systematically.

Preparation

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light[6][7]. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days[7]. Allow vials to reach room temperature before opening to minimize condensation uptake. Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed

Storage

Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements. Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Anti‑inflammatory activity

Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation

Oral and subcutaneous efficacy

Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability

Wound healing support

Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation

Generally well tolerated

Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols

No melanotropic effects

Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation.